Compare Estee Lauder Companies Inc (EL) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs Tango Therapeutics Inc. — how do they compare? Estee Lauder Companies Inc trades at $102.2 (market cap $36.81B), while Tango Therapeutics Inc. trades at $22.3 (market cap $3.74B). The key difference: Estee Lauder Companies Inc is far larger — about 9.8× Tango Therapeutics Inc.'s market cap, and Estee Lauder Companies Inc pays a 1.38% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Estee Lauder Companies Inc for 123 Days and Tango Therapeutics Inc. for 0 Days on average.
| EL | TNGX | |
|---|---|---|
Market Cap | $36.81B | $3.74B |
Volume | 2,214,573 | 3,438,781 |
Sector | Consumer Staples | Health |
52-Week High | $119.61 | $32.90 |
52-Week Low | $67.23 | $7.50 |
Typical Hold Time | 123 Days | 0 Days |
Enterprise Value | $42.56B | $2.76B |
Dividend Yield | 1.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Estée Lauder (EL) trades at $99.73, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company shows mixed fundamentals with a high P/E ratio of 199.46 but strong gross margins of 75.5%. Recent earnings beats and a strategic AI partnership with Profound highlight operational momentum, though 2025 saw a net loss of $1.13B. Analyst consensus is positive with a $103 price target and 48% buy ratings.
The outlook remains cautiously optimistic as EL navigates margin recovery and digital transformation. Key opportunities include brand innovation and AI integration, while risks involve persistent profitability challenges and competitive pressures. The stock's current level near resistance at $102 suggests near-term consolidation potential.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
